Spratt, D E
Jackson, W C
Abugharib, A
Tomlins, S A
Dess, R T
Soni, P D
Lee, J Y
Zhao, S G
Cole, A I
Zumsteg, Z S
Sandler, H
Hamstra, D
Hearn, J W
Palapattu, G
Mehra, R
Morgan, T M
Feng, F Y
Article History
Received: 26 February 2016
Revised: 22 March 2016
Accepted: 18 April 2016
First Online: 24 May 2016
Competing interests
: DES was supported by the Prostate Cancer Foundation Young Investigator Award. RM was supported by the Prostate Cancer Foundation Young Investigator Award. SAT served on the advisory boards of: Medivation/Astellas and Janssen; and received grant funding from: A. Alfred Taubman Medical Research Institute. FYF served on the advisory boards of: Medivation/Astellas, GenomeDx, Nanostring and Celgene; and received grant funding from: Varian, Medivation/Astellas and Celgene. TMM served on the advisory boards of: MDxHealth and Myriad Genetics; received research funding from: MDxHealth and Myriad Genetics; and was supported by the Prostate Cancer Foundation Young Investigator Award and by the A. Alfred Taubman Medical Research Institute. HMS consulted for: Janssen, Medivation/Astellas, Sanofi, Ferring, Clovis Oncology and Varian. The remaining authors declare no conflict of interest.